Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:52 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT04781374 · Beth Israel Deaconess Medical Center · PHASE2 · withdrawn · last registry update 2023-07-11 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Withdrawal of funding” | – | Registry record, Beth Israel Deaconess Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against EGFR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-07-03Phase 3 first posted: Region Skane, Afatinib/Dacomitinib + Osimertinib (NCT06486142)
- 2024-06-18Results posted on the registry: National Cancer Institute (NCI), Osimertinib (NCT06303167)
- 2024-06-04Results posted on the registry: EMD Serono Research & Development Institute, Inc., Tepotinib + Osimertinib (NCT03940703)
- 2024-05-22Results posted on the registry: Dana-Farber Cancer Institute, HKI-272 + Capecitabine (NCT01494662)
- 2024-05-16Phase 3 first posted: AstraZeneca, Dato-DXd + Osimertinib (NCT06417814)
- 2024-05-16Phase 3 first posted: Hansoh BioMedical R&D Company, HS-20117 + Aumolertinib (NCT06417008)
- 2024-04-12Results posted on the registry: Millennium Pharmaceuticals, Inc., Midazolam + TAK-788 (NCT04051827)
- 2024-04-05Phase 3 first posted: AstraZeneca, Osimertinib + Datopotamab Deruxtecan (NCT06350097)
- 2024-04-02Phase 3 first posted: Biotech Pharmaceutical Co., Ltd., Nimotuzumab injection + Placebo (NCT06343116)
- 2024-03-22Results posted on the registry: Yuhan Corporation, Lazertinib 240 mg/160 mg + Gefitinib 250 mg (NCT04248829)
- 2024-03-15Phase 3 first posted: Tianjin Hemay Pharmaceutical Co., Ltd, Hemay022+AI + Lapatinib+Capecitabine (NCT06313983)
- 2024-02-28Results posted on the registry: Janssen Research & Development, LLC, Lazertinib (NCT04075396)
- 2024-01-18Results posted on the registry: University of California, San Francisco, Osimertinib (NCT03433469)
- 2023-11-21Results posted on the registry: National Cancer Institute (NCI), Alectinib + Brigatinib (NCT03737994)
- 2023-11-18Results posted on the registry: University of California, San Francisco, Neratinib + Trastuzumab (NCT03094052)
- 2023-10-03Results posted on the registry: Takeda, Mobocertinib (NCT03807778)
- 2023-06-26Results posted on the registry: Daiichi Sankyo, Trastuzumab deruxtecan + Capecitabine (NCT03523585)
- 2023-03-21Results posted on the registry: Dana-Farber Cancer Institute, Neratinib + Fulvestrant (NCT03289039)
- 2023-03-08Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Trastuzumab and neratinib + Trastuzumab and Pertuzumab (NCT05760612)
- 2022-11-29Results posted on the registry: National Cancer Institute (NCI), Afatinib Dimaleate (NCT04439136)
- 2022-11-29Phase 3 first posted: AstraZeneca, Osimertinib (NCT05629234)
- 2022-11-22Phase 3 first posted: NRG Oncology, Carboplatin + Cisplatin (NCT05624996)
- 2022-11-14Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib (NCT05615818)
- 2022-07-28Results posted on the registry: City of Hope Medical Center, Lapatinib + Trastuzumab (NCT01273610)
- 2022-07-26Results posted on the registry: MedImmune LLC, Oleclumab + Osimertinib (NCT03381274)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision